Deerfield Management EHAB Position
ActiveDeerfield Management held their position in Enhabit, Inc. (EHAB) in Q4 2025, holding $43.8M worth of shares across 4,747,746 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
About Enhabit, Inc.
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.
Full company profile →Short Interest
2.7%
0.9 days to cover
Deerfield Management EHAB Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 4,747,746 | — | $43.8M |
| Q3 2025 | Decreased | 4,747,746 | -32,118 | $38.0M |
| Q2 2025 | Decreased | 4,779,864 | -217,882 | $46.1M |
| Q1 2025 | Decreased | 4,997,746 | -13,226 | $43.9M |
| Q4 2024 | Increased | 5,010,972 | +13,226 | $39.1M |
| Q3 2024 | Held | 4,997,746 | — | $39.5M |
| Q2 2024 | Held | 4,997,746 | — | $44.6M |
| Q1 2024 | Held | 4,997,746 | — | $58.2M |
| Q4 2023 | Held | 4,997,746 | — | $51.7M |
| Q3 2023 | Increased | 4,997,746 | +187,943 | $56.2M |
| Q2 2023 | Increased | 4,809,803 | +1,411,057 | $55.3M |
| Q1 2023 | New | 3,398,746 | +3,398,746 | $47.3M |
Frequently Asked Questions
Does Deerfield Management own EHAB?
Yes. As of Q4 2025, Deerfield Management holds 4,747,746 shares of Enhabit, Inc. (EHAB) valued at $43.8M. This data comes from their SEC 13F filing.
How many hedge funds own EHAB?
1 specialist biotech hedge fund currently holds EHAB. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy EHAB?
Deerfield Management's position in EHAB was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's EHAB position increasing or decreasing?
Deerfield Management held their EHAB position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
EHABCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →